Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor.

Hirayama F, Koshio H, Ishihara T, Hachiya S, Sugasawa K, Koga Y, Seki N, Shiraki R, Shigenaga T, Iwatsuki Y, Moritani Y, Mori K, Kadokura T, Kawasaki T, Matsumoto Y, Sakamoto S, Tsukamoto S.

J Med Chem. 2011 Dec 8;54(23):8051-65. doi: 10.1021/jm200868m. Epub 2011 Nov 11.

PMID:
21995444
2.

Optimization of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine-5-ylidene)acetamide derivatives as arginine vasopressin V2 receptor agonists and discussion of their binding modes.

Tsukamoto I, Koshio H, Orita M, Saitoh C, Yanai-Inamura H, Kitada-Nozawa C, Yamamoto E, Yatsu T, Sakamoto S, Tsukamoto S.

Bioorg Med Chem. 2009 Dec 15;17(24):8161-7. doi: 10.1016/j.bmc.2009.10.038. Epub 2009 Oct 23.

PMID:
19900813
3.

Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists.

Tsukamoto I, Koshio H, Kuramochi T, Saitoh C, Yanai-Inamura H, Kitada-Nozawa C, Yamamoto E, Yatsu T, Shimada Y, Sakamoto S, Tsukamoto S.

Bioorg Med Chem. 2009 Apr 15;17(8):3130-41. doi: 10.1016/j.bmc.2009.03.001. Epub 2009 Mar 9.

PMID:
19321349
4.

Preparation of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetamide derivatives as novel arginine vasopressin V(2) receptor agonists.

Tsukamoto I, Koshio H, Akamatsu S, Kuramochi T, Saitoh C, Yatsu T, Yanai-Inamura H, Kitada C, Yamamoto E, Sakamoto S, Tsukamoto S.

Bioorg Med Chem. 2008 Nov 1;16(21):9524-35. doi: 10.1016/j.bmc.2008.09.039. Epub 2008 Sep 17.

PMID:
18835174
5.

Prodrug-based design, synthesis, and biological evaluation of N-benzenesulfonylpiperidine derivatives as novel, orally active factor Xa inhibitors.

Ishihara T, Seki N, Hirayama F, Orita M, Koshio H, Taniuchi Y, Sakai-Moritani Y, Iwatsuki Y, Kaku S, Kawasaki T, Matsumoto Y, Tsukamoto S.

Bioorg Med Chem. 2007 Jun 15;15(12):4175-92. Epub 2007 Mar 25.

PMID:
17416533
6.

An easy access to 7-methyl-2-naphthalenecarbonitrile.

Koshio H, Ishihara T, Yamada H, Hirayama F, Matsumoto Y, Yanagisawa I.

Chem Pharm Bull (Tokyo). 2005 Apr;53(4):448-50.

7.

Synthesis and biological activity of novel 1,2-disubstituted benzene derivatives as factor Xa inhibitors.

Koshio H, Hirayama F, Ishihara T, Shiraki R, Shigenaga T, Taniuchi Y, Sato K, Moritani Y, Iwatsuki Y, Kaku S, Katayama N, Kawasaki T, Matsumoto Y, Sakamoto S, Tsukamoto S.

Bioorg Med Chem. 2005 Feb 15;13(4):1305-23.

PMID:
15670939
8.

Orally active factor Xa inhibitor: synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives.

Koshio H, Hirayama F, Ishihara T, Kaizawa H, Shigenaga T, Taniuchi Y, Sato K, Moritani Y, Iwatsuki Y, Uemura T, Kaku S, Kawasaki T, Matsumoto Y, Sakamoto S, Tsukamoto S.

Bioorg Med Chem. 2004 Oct 15;12(20):5415-26.

PMID:
15388168
9.

Synthesis and biological activity of novel 1,4-diazepane derivatives as factor Xa inhibitor with potent anticoagulant and antithrombotic activity.

Koshio H, Hirayama F, Ishihara T, Taniuchi Y, Sato K, Sakai-Moritani Y, Kaku S, Kawasaki T, Matsumoto Y, Sakamoto S, Tsukamoto S.

Bioorg Med Chem. 2004 May 1;12(9):2179-91.

PMID:
15080918
10.

New thiazole derivatives as potent and selective 5-hydroxytriptamine 3 (5-HT3) receptor agonists for the treatment of constipation.

Imanishi N, Iwaoka K, Koshio H, Nagashima SY, Kazuta K, Ohta M, Sakamoto S, Ito H, Akuzawa S, Kiso T, Tsukamoto S, Mase T.

Bioorg Med Chem. 2003 Apr 3;11(7):1493-502.

PMID:
12628674
11.

Design, synthesis and biological activity of YM-60828 derivatives. Part 2: potent and orally-bioavailable factor Xa inhibitors based on benzothiadiazine-4-one template.

Hirayama F, Koshio H, Katayama N, Ishihara T, Kaizawa H, Taniuchi Y, Sato K, Sakai-Moritani Y, Kaku S, Kurihara H, Kawasaki T, Matsumoto Y, Sakamoto S, Tsukamoto S.

Bioorg Med Chem. 2003 Feb 6;11(3):367-81.

PMID:
12517432
12.

Design, synthesis and biological activity of YM-60828 derivatives: potent and orally-bioavailable factor Xa inhibitors based on naphthoanilide and naphthalensulfonanilide templates.

Hirayama F, Koshio H, Ishihara T, Watanuki S, Hachiya S, Kaizawa H, Kuramochi T, Katayama N, Kurihara H, Taniuchi Y, Sato K, Sakai-Moritani Y, Kaku S, Kawasaki T, Matsumoto Y, Sakamoto S, Tsukamoto S.

Bioorg Med Chem. 2002 Aug;10(8):2597-610.

PMID:
12057649
13.

The discovery of YM-60828: a potent, selective and orally-bioavailable factor Xa inhibitor.

Hirayama F, Koshio H, Katayama N, Kurihara H, Taniuchi Y, Sato K, Hisamichi N, Sakai-Moritani Y, Kawasaki T, Matsumoto Y, Yanagisawa I.

Bioorg Med Chem. 2002 May;10(5):1509-23.

PMID:
11886813
14.

Insufficiency fracture of the spine: a prospective analysis based on radiographic and scintigraphic diagnosis.

Kawaguchi S, Yamashita T, Koshio H, Kirita T, Minaki Y, Yokogushi K.

J Bone Miner Metab. 2001;19(5):312-6.

PMID:
11498734
16.

Comparison of the anticoagulant and antithrombotic effects of YM-75466, a novel orally-active factor Xa inhibitor, and warfarin in mice.

Sato K, Taniuchi Y, Kawasaki T, Hirayama F, Koshio H, Matsumoto Y, Iizumi Y.

Jpn J Pharmacol. 1998 Oct;78(2):191-7.

17.
18.

Antithrombotic effect of YM-75466 is separated from its effect on bleeding time and coagulation time.

Sato K, Kaku S, Hirayama F, Koshio H, Matsumoto Y, Kawasaki T, Iizumi Y.

Eur J Pharmacol. 1998 Jul 3;352(1):59-63.

PMID:
9718268
19.

Antithrombotic effects of YM-60828 in three thrombosis models in guinea pigs.

Sato K, Kawasaki T, Hisamichi N, Taniuchi Y, Hirayama F, Koshio H, Ichihara M, Matsumoto Y.

Eur J Pharmacol. 1998 May 29;350(1):87-91.

PMID:
9683019
20.

Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats.

Sato K, Taniuchi Y, Kawasaki T, Hirayama F, Koshio H, Matsumoto Y.

Eur J Pharmacol. 1998 Apr 24;347(2-3):231-6.

PMID:
9653887
22.

Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa.

Taniuchi Y, Sakai Y, Hisamichi N, Kayama M, Mano Y, Sato K, Hirayama F, Koshio H, Matsumoto Y, Kawasaki T.

Thromb Haemost. 1998 Mar;79(3):543-8.

PMID:
9531037
23.

Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis.

Kawasaki T, Sato K, Sakai Y, Hirayama F, Koshio H, Taniuchi Y, Matsumoto Y.

Thromb Haemost. 1998 Feb;79(2):410-6.

PMID:
9493600
24.

Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time.

Sato K, Kawasaki T, Hisamichi N, Taniuchi Y, Hirayama F, Koshio H, Matsumoto Y.

Br J Pharmacol. 1998 Jan;123(1):92-6.

25.

YM-60828, a novel factor Xa inhibitor: separation of its antithrombotic effects from its prolongation of bleeding time.

Sato K, Kawasaki T, Taniuchi Y, Hirayama F, Koshio H, Matsumoto Y.

Eur J Pharmacol. 1997 Nov 27;339(2-3):141-6.

PMID:
9473127
26.

Biological activity of analogues of YM022. Novel (3-amino substituted phenyl)urea derivatives of 1,4-benzodiazepin-2-one as gastrin/cholecystokinin-B receptor antagonists.

Satoh M, Okamoto Y, Koshio H, Ohta M, Nishida A, Akuzawa S, Miyata K, Mase T, Semple G.

Chem Pharm Bull (Tokyo). 1996 Jul;44(7):1412-4.

PMID:
8706146
27.

[Color correspondence between upper anterior teeth and premolars based on data from the dental color analyzer].

Ogiso A, Maeda I, Marui Y, Fujii T, Fujimoto A, Koshio H, Kurachi M.

Gifu Shika Gakkai Zasshi. 1983 Aug;11(1):148-56. Japanese. No abstract available.

PMID:
6582126

Supplemental Content

Loading ...
Support Center